Back to results
US 11,628,167 B2Granted
Method of treating fibrosis
AssigneeEndeavor BioMedicines, Inc.
InventorsMiguel de los Rios, John Hood, Anita Difrancesco
Life of this patent
Estimating the term…
Abstract
The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment.
Claims18
A method of treating fibrosis comprising administering 50-200 mg of a Gli1 inhibitor to a patient in need thereof, wherein said Gli1 inhibitor is a compound of Formula 1;
- wherein, R1 is hydrogen or methyl;
- R2 is hydrogen or methyl;
- R3, R4, R5, R6, or R7 are independently hydrogen, fluoro, chloro, cyano, trifluoromethyl, trifluoromethoxy, difluoromethoxy, methylsulfonyl, or trifluoromethylsulfonyl, provided that at least three of R3, R4, R5, R6, and R7 are hydrogen;
- or a pharmaceutically acceptable salt thereof, or Formula 2:
- wherein, R1 is hydrogen or methyl;
- R2 is hydrogen or methyl;
- R3, R4, R5, R6, or R7 are independently hydrogen, fluoro, chloro, cyano, trifluoromethyl, trifluoromethoxy, difluoromethoxy, methylsulfonyl, or trifluoromethylsulfonyl, provided that at least three of R3, R4, R5, R6, and R7 are hydrogen;
- or a pharmaceutically acceptable salt thereof.
5 more elements
Dependencies are inferred from the claim text.